A Cheap, Overlooked Blood Test May Beat Standard Cholesterol Screening at Preventing Heart Attacks

A simple, inexpensive blood test that most patients have never heard of may do a better job of preventing heart attacks and strokes than the standard cholesterol screening that has guided treatment for decades, according to a new study. Researchers reported that measuring apolipoprotein B, or apoB, is more effective than tracking LDL or non-HDL cholesterol when deciding whether a patient needs more aggressive treatment.

The reason comes down to what each test actually counts. Standard tests measure the amount of cholesterol carried in the blood, but heart disease is driven by the number of harmful particles that can burrow into artery walls and form plaque. Every one of those harmful particles carries exactly one apoB molecule on its surface, so measuring apoB essentially tallies the total number of plaque-producing particles directly, rather than estimating their cargo.

That distinction matters because two people can have identical LDL cholesterol readings but very different numbers of dangerous particles, meaning one faces a substantially higher risk that a conventional test would miss. In the study, published in the journal JAMA, apoB outperformed both LDL and non-HDL cholesterol at identifying which patients would benefit from intensifying cholesterol-lowering therapy, including statins and newer medications.

Researchers at Northwestern University, who led the analysis, found that switching to apoB-guided treatment could prevent more heart attacks and strokes while remaining cost-effective for the U.S. health care system. The test itself is cheap and widely available on existing lab equipment, yet it is rarely ordered — meaning millions of people may effectively be getting the wrong cholesterol test to gauge their true cardiovascular risk.

Cardiovascular disease remains the leading cause of death in the United States, and cholesterol management is one of medicine's most common interventions, involving tens of millions of prescriptions each year. Even modest improvements in how doctors target that treatment could translate into large numbers of prevented events across the population, the authors argued.

The findings add to a growing push among some cardiologists to make apoB a routine part of cholesterol screening rather than a specialist's afterthought. Barriers remain — clinical guidelines, insurance habits and physician familiarity all favor the older LDL test — but the study strengthens the case that a low-cost tweak to a routine blood draw could sharpen who gets aggressive treatment and, ultimately, save lives. For patients, the practical takeaway is straightforward: apoB is not an exotic new procedure but the same simple blood draw, analyzed in a way that more accurately reflects the danger lurking in the arteries. Experts say the next step is updating clinical guidelines and reimbursement policies so that the test moves from the margins of cardiology into everyday primary care, where the vast majority of cholesterol decisions are actually made.